Lauren Hanna, MD
Family Medicine · West Liberty, IANPI 1518909787
Payments from drug & device makers
Across 243 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$433
- Pfizer$423
- AstraZeneca$391
- Novo Nordisk$382
- AbbVie$345
- GSK$264
- plus $2K from 24 others
What the payments were for
- Food & beverage$3,86397%
- Education$1133%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 27 | $433 |
| Pfizer | 25 | $423 |
| AstraZeneca | 26 | $391 |
| Novo Nordisk | 25 | $382 |
| AbbVie(2 entities) | 22 | $345 |
| GSK | 16 | $264 |
| Boehringer Ingelheim | 13 | $241 |
| Astellas Pharma US Inc | 8 | $224 |
| Lilly USA, LLC | 10 | $174 |
| Merck | 8 | $98 |
| Johnson & Johnson | 7 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $97 |
| Mylan Specialty L.p. | 6 | $97 |
| Exact Sciences | 4 | $84 |
| Novartis | 6 | $80 |
| Biohaven Pharmaceuticals, Inc. | 4 | $71 |
| Kowa Pharmaceuticals America, Inc. | 4 | $68 |
| Esperion Therapeutics, Inc. | 4 | $63 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $61 |
| Abbott | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $44 |
| Amarin Pharma, Inc. | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Coopersurgical, Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Bayer | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$3,976 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 61 | $62,751 |
| EliquisApixaban | 55 | $46,694 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $29,909 |
| XareltoRivaroxaban | 26 | $21,317 |
| LinzessLinaclotide | 21 | $20,420 |
| JardianceEmpagliflozin | 14 | $19,140 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $18,210 |
| OzempicSemaglutide | 19 | $17,499 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $15,449 |
| TradjentaLinagliptin | 17 | $14,216 |
| JanuviaSitagliptin Phosphate | 11 | $13,282 |
| TrulicityDulaglutide | 13 | $12,335 |
| MyrbetriqMirabegron | 15 | $11,401 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $9,419 |
| EntrestoSacubitril/Valsartan | 12 | $9,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $391 | $62,75161 claims |
| PfizerEliquis | $423 | $46,69455 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $264 | $35,80558 claims |
| Boehringer IngelheimJardiance, Tradjenta | $241 | $33,35631 claims |
| MerckJanumet Xr, Januvia | $98 | $31,49230 claims |
| Johnson & JohnsonXarelto | $98 | $21,31726 claims |
| AbbVieLinzess | $345 | $20,42021 claims |
| Novo NordiskOzempic | $382 | $17,49919 claims |
| Lilly USA, LLCTrulicity | $174 | $12,33513 claims |
| Astellas Pharma US IncMyrbetriq | $224 | $11,40115 claims |
| NovartisEntresto | $80 | $9,31412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in West Liberty
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Nicholas BechtoldSioux City$584K
- Kirk PetersonHuxley$576K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
- Carlos Alarcon SchroderJohnston$237K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.